Cabozantinib + Pembrolizumab for Melanoma
Trial Summary
Will I have to stop taking my current medications?
The trial requires a 2-week washout period (time without taking certain medications) for those who have taken BRAF and/or MEK inhibitors. Additionally, you cannot take certain medications like strong CYP3A4 inducers or inhibitors close to the start of the trial. Other medications may also need to be stopped, but the protocol does not specify all details.
What data supports the effectiveness of the drug pembrolizumab for melanoma?
Is the combination of Cabozantinib and Pembrolizumab safe for treating melanoma?
Pembrolizumab, also known as KEYTRUDA, has been shown to be generally safe in humans with advanced melanoma, with common side effects including fatigue, rash, itching, and diarrhea. Less common side effects can include thyroid issues, inflammation of the colon, liver, or lungs. While specific safety data for the combination with Cabozantinib is not provided, Pembrolizumab alone has a favorable safety profile.26789
How is the drug combination of Cabozantinib and Pembrolizumab unique for treating melanoma?
The combination of Cabozantinib and Pembrolizumab is unique because it pairs a tyrosine kinase inhibitor (Cabozantinib) with an immune checkpoint inhibitor (Pembrolizumab), potentially enhancing the immune system's ability to fight melanoma by targeting different pathways. This approach is novel compared to traditional treatments that often focus on a single mechanism.1261011
What is the purpose of this trial?
This trial is testing a combination of two drugs to treat adults with advanced melanoma that cannot be surgically removed. One drug stops cancer cells from growing, and the other helps the immune system attack the cancer. The combination of pembrolizumab and ipilimumab is being tested for its effectiveness and safety in treating advanced melanoma.
Research Team
John Rieth, MD
Principal Investigator
University of Iowa
Eligibility Criteria
Adults with advanced melanoma who can swallow pills, have measurable lesions, and haven't had certain treatments for their cancer recently. They must understand the study and agree to provide tissue samples. Women of childbearing age need a negative pregnancy test.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1b Treatment
Establish the recommended Phase 2 dose of cabozantinib in combination with pembrolizumab and assess safety and tolerability
Phase 2 Treatment
Evaluate the preliminary efficacy of the established dose of cabozantinib in combination with pembrolizumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cabozantinib
- Pembrolizumab
Cabozantinib is already approved in European Union, United States, Canada, Japan for the following indications:
- Renal cell carcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
John Rieth
Lead Sponsor
Yousef Zakharia
Lead Sponsor
University of Iowa
Collaborator
Exelixis
Industry Sponsor
Michael M. Morrissey
Exelixis
Chief Executive Officer since 2010
PhD in Chemistry from Harvard University, BSc in Chemistry from the University of Wisconsin
Vicki L. Goodman
Exelixis
Chief Medical Officer since 2022
MD